ArticleGeroScience2024
Anticipating the future of the COVID-19 pandemic: insights into the emergence of SARS-CoV-2 variant JN.1 and its projected impact on older adults.
Article in GeroScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Broad cross-T cell immunity between emerging SARS-CoV-2 serotypes waved by spike-signature mutations.Emerging microbes & infections · 2026Article
- The Role of Immunosenescence and Inflammaging in the Susceptibility of Older Adults to SARS-CoV-2 Infection.Current pharmaceutical biotechnology · 2026Review
- Optimization of the Primary Sludge Processing Method for Wastewater Genomic Surveillance of SARS-CoV‑2.ACS ES&T water · 2025Article
- Real-Time PCR-Based Test as a Research Tool for the Retrospective Detection and Identification of SARS-CoV-2 Variants of Concern in a Sample.International journal of molecular sciences · 2025Article
- Fortifying defenses: Tactical safety protocols for COVID-19 sub-variant JN.1 in healthcare and laboratory settings.Journal of family medicine and primary care · 2025Article
- Article
- Evaluation of the Content Validity of the COVID-19 Symptoms Daily Diary.Patient related outcome measures · 2025Article
- Daphnetin may protect from SARS-CoV-2 infection by reducing ACE2.Scientific reports · 2024Article
- Article
- SARS-CoV-2 and Environmental Changes: The Perfect Storm.Current issues in molecular biology · 2024Review
- Review
- COVID-19: vaccination, therapeutics and a review of the science and public health.Annals of medicine and surgery (2012) · 2024Review
- Review
- Global spread of COVID-19's JN.1 variant: Implications and public health responses.New microbes and new infections · 2024Article
- The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health.Therapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.